Anti-IgE in severe persistent allergic asthma

Respirology

Volumn 12, Issue SUPPL. 3, 2007, Pages

  Fox, Howard ^a  

^a NOVARTIS HORSHAM RESEARCH CENTRE   (United Kingdom)

Author keywords

Anti IgE; Asthma; Omalizumab

Indexed keywords

BECLOMETASONE DIPROPIONATE; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; IMMUNOGLOBULIN E ANTIBODY; IMMUNOGLOBULIN E RECEPTOR; OMALIZUMAB;

ADD ON THERAPY; CLINICAL TRIAL; CONFERENCE PAPER; DISEASE EXACERBATION; DRUG EFFECT; DRUG RECEPTOR BINDING; FORCED EXPIRATORY VOLUME; HEALTH CARE UTILIZATION; HUMAN; LUNG FUNCTION; PATIENT ASSESSMENT; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; QUALITY OF LIFE; SEVERE PERSISTENT ASTHMA; STATISTICAL SIGNIFICANCE; SYMPTOM; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ANTI-ASTHMATIC AGENTS; ANTIBODIES, MONOCLONAL; ASTHMA; CLINICAL TRIALS AS TOPIC; HEALTH CARE COSTS; HUMANS; IMMUNOGLOBULIN E; INTERNATIONAL AGENCIES; QUALITY OF LIFE; TREATMENT OUTCOME; WORLD HEALTH;

EID: 35448947319     PISSN: 13237799     EISSN: 14401843     Source Type: Journal    
DOI: 10.1111/j.1440-1843.2007.01016.x     Document Type: Conference Paper

References (13)

1. Fahy JV, Fleming HE, Wong HH, Liu JT, Su JQ, et al. The effect of an anti-IgE monoclonal antibody on the early- and late-phase responses to allergen inhalation in asthmatic subjects. Am. J. Respir. Crit. Care Med. 1997 155 : 1828 34.
2. MacGlashan DW Jr, Bochner BS, Adelman DC, Jardieu PM, Togias A, et al. Down-regulation of Fc(epsilon)RI expression on human basophils during in vivo treatment of atopic patients with anti-IgE antibody. J. Immunol. 1997 158 : 1438 45.
3. Djukanović R, Wilson SJ, Kraft M, Jarjour NN, Steel M, et al. Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma. Am. J. Respir. Crit. Care Med. 2004 170 : 583 93.
4. Burrows B, Martinez FD, Halonen M, Barbee R, Cline MG. Association of asthma with serum IgE levels and skin-test reactivity to allergens. N. Engl. J. Med. 1989 320 : 271 7.
5. Novak N, Bieber T. Allergic and nonallergic forms of atopic diseases. J. Allergy Clin. Immunol. 2003 112 : 252 62.
6. European Network for Understanding Mechanisms of Severe Asthma. The ENFUMOSA cross-sectional European multicentre study of the clinical phenotype of chronic severe asthma. Eur. Respir. J. 2003 22 : 470 7.
7. Humbert M, Beasley R, Ayres J, Slavin R, Hebert J, et al. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy 2005 60 : 309 16.
8. Ayres JG, Higgins B, Chilvers ER, Ayre G, Blogg M, et al. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with poorly controlled (moderate-to-severe) allergic asthma. Allergy 2004 59 : 701 8.
9. Vignola AM, Humbert M, Bousquet J, Boulet LP, Hedgecock S, et al. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLAR. Allergy 2004 59 : 709 17.
10. Busse W, Corren J, Lanier BQ, McAlary M, Fowler-Taylor A, et al. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J. Allergy Clin. Immunol. 2001 108 : 184 90.
11. Solèr M, Matz J, Townley R, Buhl R, O'Brien J, et al. The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. Eur. Respir. J. 2001 18 : 254 61. Erratum in: Eur. Respir. J. 2001; 18 : 739-40.
12. Holgate ST, Chuchalin AG, Hebert J, Lotvall J, Persson GB, et al. on behalf of the Omalizumab 011 International Study Group. Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma. Clin. Exp. Allergy 2004 34 : 632 8.
13. Bousquet J, Cabrera P, Berkman N, Buhl R, Holgate S, et al. The effect of treatment with omalizumab, an anti-IgE antibody, on asthma exacerbations and emergency medical visits in patients with severe persistent asthma. Allergy 2005 60 : 302 8.